Zaheed Tai, DO
Cardiovascular Disease · Winter Haven, FLNPI 1487611299
Payments from drug & device makers
Across 336 payments — averaging $379.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$69K
- Angiodynamics, Inc.$25K
- Boston Scientific$21K
- Philips North America LLC$6K
- Medtronic$2K
- Penumbra, Inc.$962
- plus $3K from 27 others
What the payments were for
- Consulting fees$3,0002%
- Speaking & faculty fees$84,20069%
- Travel & lodging$5,0884%
- Food & beverage$10,6999%
- Education$4,0283%
- Gifts$1090%
- Other$15,73313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 76 | $69,128 |
| Angiodynamics, Inc. | 8 | $24,556 |
| Boston Scientific | 49 | $21,347 |
| Philips North America LLC | 5 | $6,039 |
| Medtronic(2 entities) | 37 | $1,988 |
| Penumbra, Inc. | 8 | $962 |
| Cardiovascular Systems Inc. | 61 | $870 |
| Shockwave Medical, Inc | 6 | $678 |
| Abbott | 21 | $357 |
| Edwards Lifesciences | 2 | $167 |
| W. L. Gore & Associates, Inc. | 6 | $157 |
| Teleflex LLC | 2 | $124 |
| Boehringer Ingelheim | 7 | $111 |
| Celonova Biosciences, Inc. | 1 | $100 |
| Bard Peripheral Vascular, Inc. | 3 | $89 |
| Merck | 5 | $88 |
| Johnson & Johnson | 5 | $82 |
| AstraZeneca | 5 | $80 |
| Amgen | 4 | $71 |
| Inari Medical, Inc. | 3 | $65 |
| Recor Medical Inc | 3 | $63 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $57 |
| Reflow Medical Inc | 3 | $47 |
| Acist Medical Systems, Inc. | 1 | $28 |
| Cardiva Medical, Inc. | 1 | $19 |
| Surmodics, Inc. | 1 | $18 |
| Silk Road Medical, Inc. | 1 | $14 |
| Cordis US CORP. | 1 | $14 |
| Kestra Medical Technology Services, Inc. | 1 | $14 |
| Biosense Webster, Inc. | 1 | $12 |
| Novartis | 1 | $11 |
| Cardio Flow, Inc. | 2 | $0 |
| Vantis Vascular, Inc. | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$67,293
- Auryon Laser System 100-120 Vac$15,733
- GENERAL VASCULAR ACCESS$10,000
- Auryon$4,028
- CROSSBOSS$3,500
- US Und$3,000
- CVX-300$3,000
- CoreValve Evolut$1,250
- GENERAL - THERAPIES$843
- Indigo$775
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$457
- Vascular Lithotripsy$176
- OPTICROSS$170
- Legacy$134
- SAPIEN 3 Ultra RESILIA$132
- GENERAL - STENTS$119
- TURNPIKE$113
- VIABAHN Endoprosthesis$111
- COREVALVE EVOLUT R$102
How this compares
$127,357 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 660 | $647,711 |
| EntrestoSacubitril/Valsartan | 451 | $437,026 |
| XareltoRivaroxaban | 160 | $189,213 |
| BrilintaTicagrelor | 161 | $117,537 |
| FarxigaDapagliflozin Propanediol | 134 | $110,090 |
| JardianceEmpagliflozin | 120 | $97,140 |
| Repatha SureclickEvolocumab | 98 | $76,179 |
| NexletolBempedoic Acid | 37 | $15,912 |
| Praluent PenAlirocumab | 12 | $14,707 |
| Ranolazine ErRanolazine | 184 | $14,252 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 71 | $13,278 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $9,724 |
| Metoprolol Succinate | 565 | $7,083 |
| ClopidogrelClopidogrel Bisulfate | 724 | $6,627 |
| Dofetilide | 17 | $3,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $11 | $437,026451 claims |
| AstraZenecaBrilinta, Farxiga | $80 | $227,628295 claims |
| Johnson & JohnsonXarelto | $82 | $189,213160 claims |
| Boehringer IngelheimJardiance, Pradaxa | $111 | $99,661133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Winter Haven
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
- Duccio BaldariWellington$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.